TRVI Stock Analysis: Buy, Sell, or Hold?
TRVI - Trevi Therapeutics, Inc. Common Stock
$17.96
-0.29 (-1.59%)
âŧ
5d:
-2.71%
30d:
+4.54%
90d:
+26.84%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 19, 2026 at $18.81 · last confirmed Aug 21, 2026
Strength: 4.0/10
Get Alerted When TRVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TRVI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TRVI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TRVI is currently trading at $17.96, which is considered fair relative to its 30-day fair value range of $17.47 to $18.67.
Technical Outlook: Technically, TRVI is in a strong uptrend. The price is currently testing key support at $17.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TRVI scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.18 (+56.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRVI is in a strong uptrend. The price is currently testing key support at $17.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TRVI scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.18 (+56.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$17.47 -
$18.67
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding TRVI? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 56.9% below Wall St target ($28.18)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.47 -
$18.67
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$17.52
Resistance Level
$19.30
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-31.13
Wall Street Target
$28.18
(+56.9%)
Share & Embed Analysis
Last updated: August 23, 2026 6:27 AM ET
Data refreshes hourly during market hours. Next update: 7:27 AM
Data refreshes hourly during market hours. Next update: 7:27 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
Advanced TRVI Option Strategies
Professional options setups generated by AI based on today's TRVI price and gamma walls.
